340 related articles for article (PubMed ID: 12714807)
1. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D
Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
3. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
Lister PD
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
[TBL] [Abstract][Full Text] [Related]
6. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.
Lawrence LE; Frosco M; Ryan B; Chaniewski S; Yang H; Hooper DC; Barrett JF
Antimicrob Agents Chemother; 2002 Jan; 46(1):191-5. PubMed ID: 11751133
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
Yamakawa T; Mitsuyama J; Hayashi K
J Antimicrob Chemother; 2002 Mar; 49(3):455-65. PubMed ID: 11864945
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
Galles AC; Jones RN; Sader HS
J Chemother; 2008 Feb; 20(1):38-42. PubMed ID: 18343741
[TBL] [Abstract][Full Text] [Related]
14. Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
Shi G; Chen X; Wang H; Wang S; Guo X; Zhang X
J Antibiot (Tokyo); 2012 May; 65(5):229-36. PubMed ID: 22334239
[TBL] [Abstract][Full Text] [Related]
15. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.
Farrell DJ; Liverman LC; Biedenbach DJ; Jones RN
Antimicrob Agents Chemother; 2011 Jul; 55(7):3631-4. PubMed ID: 21555765
[TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
17. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.
Simoens S; Verhaegen J; van Bleyenbergh P; Peetermans WE; Decramer M
Antimicrob Agents Chemother; 2011 Jun; 55(6):3051-3. PubMed ID: 21464243
[TBL] [Abstract][Full Text] [Related]
18. Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes.
Van de Velde S; Nguyen HA; Van Bambeke F; Tulkens PM; Grellet J; Dubois V; Quentin C; Saux MC
J Antimicrob Chemother; 2008 Sep; 62(3):518-21. PubMed ID: 18544595
[TBL] [Abstract][Full Text] [Related]
19. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Blondeau JM; Borsos S; Hesje CK
J Chemother; 2007 Apr; 19(2):146-51. PubMed ID: 17434822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
